Editorial: Resistance to Endocrine Therapies in Cancer

Prathibha Ranganathan; Anindita Chakrabarty; Stephen Hiscox; Anil Mukund Limaye; Veronica Vella

doi:10.3389/fendo.2020.00196

Editorial: Resistance to Endocrine Therapies in Cancer

Front Endocrinol (Lausanne). 2020 Apr 9:11:196. doi: 10.3389/fendo.2020.00196. eCollection 2020.

Authors

Prathibha Ranganathan¹, Anindita Chakrabarty², Stephen Hiscox³, Anil Mukund Limaye⁴, Veronica Vella⁵

Affiliations

¹ Centre for Human Genetics, Bengaluru, India.
² Department of Life Sciences, Shiv Nadar University, Greater Noida, India.
³ School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, United Kingdom.
⁴ Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, India.
⁵ Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, Catania, Italy.

No abstract available

Keywords: drug resistance; endocrine therapy; estrogen receptor; growth factor signaling; hormone ablation; non-canonical signaling; tumor microenvironment.

Publication types

Editorial
Introductory Journal Article

MeSH terms

Antineoplastic Agents, Hormonal / therapeutic use*
Biomedical Research / methods
Biomedical Research / trends
Drug Resistance, Neoplasm / physiology*
Humans
Neoplasms / diagnosis
Neoplasms / drug therapy*
Neoplasms / pathology
Signal Transduction / drug effects

Substances

Antineoplastic Agents, Hormonal